$335.110
-1.407 (-0.42%)Zum Schluss
LH-News
LH-Events
Labcorp Enhances Digital Experience of Global Trial Connect
Labcorp announced enhancements to the digital experience of Labcorp Global Trial Connect. The newly redesigned platform introduces new capabilities across the Labcorp Sponsor and Labcorp Investigator portal experiences of Global Trial Connect.
Labcorp Enhances Digital Experience of Global Trial Connect
Labcorp announced enhancements to the digital experience of Labcorp Global Trial Connect. The redesigned platform introduces new capabilities across the Labcorp Sponsor and Labcorp Investigator portal experiences of Global Trial Connect.
Labcorp Launches FDA-Cleared Elecsys pTau-217 Test
Labcorp (LH) announced it will offer the Elecsys pTau-217 test following clearance by the U.S. FDA. Developed by Roche Diagnostics (RHHBY), the blood test aids in identifying amyloid pathology associated with Alzheimer's disease in individuals 55 and older with signs, symptoms or complaints of cognitive decline. Elecsys pTau-217 is the first and only FDA-cleared single-biomarker blood test to both rule in and rule out amyloid pathology across specialty and primary care settings.
Labcorp Launches Roche's PTEN Test Nationwide
Labcorp (LH) announced the nationwide availability of Roche's (RHHBY) VENTANA PTEN (SP218) RxDx Assay, the first immunohistochemistry companion diagnostic test approved by the U.S. FDA to determine PTEN protein loss, also known as PTEN deficiency, in tumors of patients with prostate adenocarcinoma. The assay helps identify patients who may be eligible for treatment with AstraZeneca's TRUQAP in combination with abiraterone acetate and prednisone.
Labcorp Reports Q2 Revenue of $3.73B, Beating Expectations
Reports Q2 revenue $3.73B, consensus $3.71B. "Labcorp delivered another very strong quarter, with 6% revenue growth, significant margin expansion, and double-digit adjusted EPS growth reflecting continued momentum across the business," said Adam Schechter, Chairman and CEO of Labcorp. "During the second quarter, we expanded our leadership in oncology and other high-growth specialty areas, strengthened our position as the partner of choice for health systems, biopharmaceutical companies, and regional/local laboratories, and advanced our use of technology to improve the experience for consumers and providers. Our performance and continued execution position us well to deliver sustainable growth and long-term value for customers and shareholders."
Diese Seite dient nur der Recherche und ist keine Anlageberatung. Modelle können falsch liegen. Vergangene Wertentwicklung ist kein Indikator für die Zukunft.